Top Pharma Stocks with High FII Holding

The table below shows Top Pharma Stocks with High FII Holding based on the Highest Market Capitalization.

What Are The Pharma Stocks with High FII Holding?

Pharma stocks with high FII (Foreign Institutional Investor) holdings are shares of pharmaceutical companies that have attracted significant investment from foreign institutional investors. These stocks typically represent well-established companies with strong market positions, robust research and development capabilities, and growth potential in the pharmaceutical industry.

High FII holding often indicates that these companies have met international investment standards and are considered attractive by global investors. It may reflect factors such as strong product pipelines, global market presence, or innovative drug development programs.

However, it’s important to note that FII holdings can fluctuate, and high foreign investment doesn’t guarantee future performance. Investors should conduct thorough research and consider various factors beyond FII holding when making investment decisions in the pharmaceutical sector.

Features Of Top Pharma Stocks with High FII Holding

The main features of top Pharma stocks with high FII holding include strong research capabilities, diverse product portfolios, global market presence, regulatory compliance, and growth potential. These characteristics make them attractive to both foreign and domestic investors seeking exposure to the pharmaceutical sector.

• Innovation Powerhouses: These companies typically have robust research and development capabilities. They invest heavily in developing new drugs and therapies, which can lead to breakthrough treatments and long-term growth opportunities.

• Diverse Product Mix: Top pharma stocks often have a well-diversified product portfolio. This includes a mix of patented drugs, generics, and over-the-counter medications, providing revenue stability and growth potential across various market segments.

• Global Footprint: High FII holding often indicates companies with significant international operations. These firms are well-positioned to benefit from global healthcare trends and have access to diverse markets.

• Regulatory Excellence: FIIs typically favor companies with strong regulatory compliance records. These stocks often represent firms that successfully navigate complex regulatory environments in multiple countries.

• Financial Health: These companies usually demonstrate solid financial performance with strong cash flows, healthy profit margins, and efficient capital management. Their financial strength supports ongoing research and potential acquisitions.

Best Pharma Stocks with High FII Holding

The table below shows the Best Pharma Stocks with High FII Holding based on 1 Year Return.

Top Pharma Stocks with High FII Holding in India

The table below shows the Top Pharma Stocks with High FII Holding in India based on the highest day Volume.

Factors To Consider When Investing In Top Pharma Stocks with High FII Holding

When investing in top Pharma stocks with high FII holdings, consider the company’s drug pipeline, patent portfolio, and research capabilities. Evaluate their ability to bring new drugs to market and defend existing patents. Also, assess their geographic diversification and exposure to different healthcare segments.

Analyze the regulatory environment in key markets and the company’s track record in obtaining drug approvals. Consider factors like healthcare reforms, pricing pressures, and government policies that can impact pharmaceutical companies’ profitability.

Examine the company’s financial health, including its debt levels, cash flow generation, and dividend policy. Also, consider its strategy for growth, whether through organic research and development or through mergers and acquisitions.

How To Invest In Pharma Stocks with High FII Holding?

To invest in Pharma stocks with high FII holding, start by researching companies in the sector with significant foreign institutional investment. Use financial websites or stock screeners to identify these stocks. Open an account with a reliable broker like Alice Blue to execute trades.

Conduct thorough due diligence on the shortlisted companies. Analyze their financial statements, drug pipelines, market position, and reasons for high FII interest. Consider consulting financial advisors or industry experts for insights.

Develop a diversified investment strategy. While focusing on high FII holding stocks, also consider other factors like valuation, growth potential, and risk. Implement a systematic investment plan to mitigate market timing risks.

Advantages Of Investing In Pharma Stocks with High FII Holding

The main advantages of investing in Pharma stocks with high FII holding include exposure to quality companies, potential for good returns, liquidity benefits, and access to global healthcare trends. These factors make them attractive for investors seeking exposure to the pharmaceutical sector.

• Quality Assurance: High FII holding can be seen as a vote of confidence from sophisticated international investors, indicating that the company meets global investment standards.

• Liquidity Boost: Stocks with high FII interest typically have good trading volumes, making it easier for investors to buy or sell shares without significantly impacting the stock price.

• Global Healthcare Exposure: These companies often have international operations, providing exposure to global healthcare trends and diverse market opportunities.

• Innovation Potential: FIIs often invest in companies with strong R&D capabilities, giving investors exposure to potential breakthrough treatments and long-term growth prospects.

• Financial Stability: Pharma companies with high FII holding often demonstrate strong financial performance, potentially offering stability and consistent returns to investors.

Risks Of Investing In Pharma Stocks with High FII Holding

The main risks of investing in Pharma stocks with high FII holding include regulatory challenges, patent expiration issues, R&D failures, pricing pressures, and the potential for rapid FII outflows. These factors can impact stock performance and require careful consideration.

• Regulatory Hurdles: Pharmaceutical companies face stringent regulatory oversight. Failure to obtain drug approvals or regulatory issues can significantly impact stock performance.

• Patent Cliffs: Expiration of key drug patents can lead to revenue declines as generic competition enters the market, potentially affecting the company’s profitability and stock price.

• R&D Risks: Drug development is inherently risky. Failed clinical trials or inability to bring new drugs to market can negatively impact the company’s growth prospects.

• Pricing Pressures: Increasing focus on healthcare costs can lead to pricing pressures on pharmaceutical products, potentially affecting profit margins and revenue growth.

• FII Sentiment Shifts: While high FII holding can be positive, it also poses a risk of rapid outflows if foreign sentiment changes, potentially leading to stock price volatility.

Introduction to Pharma Stocks with High FII Holding

Mankind Pharma Ltd

The Market Cap of Mankind Pharma Ltd is ₹82,643.02 crore. The stock’s 1-month return is 0.98%, while its 1-year return is 38.24%. It is currently 11.13% away from its 52-week high.

Mankind Pharma Limited is an India-based pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across acute and chronic therapeutic areas. The company’s portfolio includes formulations for anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others.

Additionally, Mankind Pharma offers products in urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral, and vaccines. The company’s brands include Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.

Lupin Ltd

The Market Cap of Lupin Ltd is ₹73,574.02 crore. The stock’s 1-month return is -4.16%, while its 1-year return is 95.92%. It is currently 7.72% away from its 52-week high.

Lupin Limited, an India-based pharmaceutical company, produces, develops, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. The company operates in segments like Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives, and Nonsteroidal Anti Inflammatory Drug therapy.

Lupin’s manufacturing locations span India, the United States, Mexico, and Brazil, with trading and related activities extending globally. Its complex generics portfolio includes Filgrastim, Pegfilgrastim, Etanercept, and Albuterol, while its biosimilar products include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim), and Etanercept. Lupin’s diabetes brands include ONDERO and ONDERO MET.

Alkem Laboratories Ltd

The Market Cap of Alkem Laboratories Ltd is ₹65,182.65 crore. The stock’s 1-month return is -2.60%, while its 1-year return is 51.27%. It is currently 9.35% away from its 52-week high.

Alkem Laboratories Limited, an India-based company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company offers products across various therapeutic areas such as Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, CNS, Oncology, Urology, Gynecology, and Vitamins, Minerals, and Nutrition.

Alkem’s product range includes Rx Products, Alkem Generics, and OTC Products. Its portfolio includes brands like Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo, and Ondem. The company operates through a segment, Pharmaceuticals, with 21 manufacturing facilities in India and the US, offering approximately 800 brands in 40 countries.

Natco Pharma Ltd

The Market Cap of Natco Pharma Ltd is ₹18,272.79 crore. The stock’s 1-month return is 18.92%, while its 1-year return is 95.27%. It is currently 1.52% away from its 52-week high.

Natco Pharma Limited, an India-based vertically integrated, research and development-focused pharmaceutical company, engages in the business of pharmaceuticals, which includes R&D, manufacturing, and selling of bulk drugs and finished dosage formulations. The company produces finished dosage formulations (FDF) sold in India, the US, and other global markets.

Natco’s capabilities encompass multi-step synthesis, semi-synthetic fusion technologies, and the production of high-potency APIs, and peptides. It operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment drives sales through FDFs and APIs, while the agrochemicals segment focuses on niche products like pest management.

Strides Pharma Science Ltd

The Market Cap of Strides Pharma Science Ltd is ₹7,889.99 crore. The stock’s 1-month return is 11.70%, while its 1-year return is 144.34%. It is currently 1.15% away from its 52-week high.

Strides Pharma Science Limited, an India-based pharmaceutical company, focuses on the development and manufacture of IP-led niche and pharmaceutical products. The company operates through two segments: Pharmaceutical and Biopharmaceutical, with geographical segments in Africa, Australia, Asia (excluding India), North America, Europe, India, and Others.

Strides manufacture a range of niche and pharmaceutical products, including dosage forms like liquids, creams, ointments, soft gels, sachets, tablets, and modified release formats. It has eight manufacturing units located in India (Bengaluru, Puducherry, and Chennai), Singapore, Italy (Milan), the US (Florida), and Kenya (Nairobi). The company is also engaged in manufacturing soft gelatin capsules and drugs for anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious diseases.

Entero Healthcare Solutions Ltd

The Market Cap of Entero Healthcare Solutions Ltd is ₹4,447.89 crore. The stock’s 1-month return is -1.45%, while its 1-year return is -10.61%. It is currently 22.42% away from its 52-week high.

Founded in 2018, Entero Healthcare Solutions aims to create an organized, technology-driven, and integrated healthcare products distribution platform in India. As one of the largest and fastest-growing healthcare product distribution platforms, it ranks among the top three in terms of revenue in FY22.

Entero has a wide operational presence across India, covering 501 districts through physical warehouses in 38 cities. It boasts the largest hospital customer network among pharmaceutical product distributors and ranks among the top three healthcare product distributors with extensive retail pharmacy reach. The company achieved the fastest operational scale-up among healthcare product distributors from FY19 to FY22.

Nectar Lifesciences Ltd

The Market Cap of Nectar Lifesciences Ltd is ₹747.91 crore. The stock’s 1-month return is 0.67%, while its 1-year return is 88.02%. It is currently 35.41% away from its 52-week high.

Nectar Lifesciences Limited, an India-based pharmaceutical company, operates in areas like active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The company manufactures oral and sterile cephalosporin products, including cefixime, cefuroxime axetil, cefpodoxime proxetil, cefprozil, and cefdinir.

Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime arginine. Nectar Lifesciences’ manufacturing capacities cover cefixime, cefuroxime axetil amorphous and crystalline, cefotaxime sodium, and ceftriaxone sodium. The company offers contract manufacturing for solid dosage forms like tablets, capsules, dry powder oral suspension, granules, and injectables for cephalosporins.

Zenith Drugs Ltd

The Market Cap of Zenith Drugs Ltd is ₹115.33 crore. The stock’s 1-month return is 10.50%, while its 1-year return is -36.95%. It is currently 72.70% away from its 52-week high.

Founded in 2000 by Late Shri Ramniklal Soni, Zenith Drugs Ltd has grown with a mission to provide high-quality, cost-effective medicines. The company operates a WHO-GMP-compliant manufacturing unit and an ISO 9001:2015 certified Quality Management System. Zenith specializes in manufacturing affordable medicines, including ORS Powder, Liquid Oral, Ointments, Creams, Gels, Capsules, and Tablets.

Zenith’s market share is supported by its subsidiaries, Biozen Healthcare and Biogenesis Corporation, in India. The company is one of the largest manufacturers of ORS sachets in central India, trusted by companies like Ajanta Pharma, Micro Labs, May & Bakers, and Troikaa, and recognized by over 10 Indian states as a consistent supplier.

Top Pharma Stocks with High FII Holding – FAQs 

We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.